The registration status of Remicade (infliximab) in Ukraine for 2026 is not publicly available through the provided information.
When does Remicade's patent expire?
The original Remicade patent has expired, allowing for the development of biosimilars. However, patent protection can be complex and may extend to specific formulations or methods of use, potentially influencing the market exclusivity of the originator product [1]. Information regarding specific patent expirations for Remicade and its biosimilars in various regions, including Ukraine, can be tracked through resources like DrugPatentWatch.com [1].
What are the alternatives to Remicade?
Alternatives to Remicade include biosimilar versions of infliximab. These biosimilars are designed to be highly similar to the reference product in terms of safety, efficacy, and quality. The availability and approval status of these biosimilars can vary by country.
How is Remicade used?
Remicade is a medication used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis [2]. It belongs to a class of drugs called TNF inhibitors, which work by reducing inflammation in the body [2].
Sources:
1. DrugPatentWatch.com
2. Remicade prescribing information